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Abstract
Background: Nearly half of all patients in the Intensive Care Unit (ICU) receive red blood cell
(pRBC) transfusions (TFs), despite their associated complications. Restrictive transfusion strategy
(Hemoglobin [Hb] < 7 g/dL) has been shown to reduce TF exposure. We estimated the potential
annual reduction in transfusion-attributable severe acute complications (TSACs) and costs across
the US ICUs with the adoption of restrictive strategy.
Methods: A model, utilizing inputs from published studies, was constructed. Step 1 calculated
potential number of patients appropriate for this strategy. In step 2, total number of pRBC units
avoided with the restrictive trigger was extrapolated to the annual TFs in the US ICUs. Step 3
quantified excess acute complications and the number of pRBC units TF/1 TSAC in the TRICC trial.
Step 4 transformed restrictive strategy-related avoidance of pRBC units to a reduction in TSACs,
and step 5 quantified the associated cost savings.
Results: Of the 4.4 million annual ICU admissions, 1,020,800 comprised the at-risk population.
The total of 1,295,126 units of pRBC ($643/unit) could be saved with the restrictive strategy. Based
on the data from the TRICC trial, dividing the 49 excess complications in the liberal group into the
calculated excess of pRBCs transfused (1,624 units) yielded the rate of 33 pRBC units per one
complication. Thus, dividing 1,295,126 units saved by 33 units/1 TSAC, the base-case analysis
showed that 39,246 TSACs could potentially be avoided annually in the US ICUs, with the cost
savings of $821,109,826.
Conclusion: This model demonstrates that a restrictive transfusion strategy in appropriate at risk
ICU patients is dominant and could result in improved quality of care and cost savings. Given the
potential savings of 40,000 TSACs and nearly $1 billion, it is incumbent upon the intensivist
community to promote more ubiquitous adoption of a clinically appropriate restrictive transfusion
strategy in the ICU.
Background
Allogeneic blood transfusion remains a cornerstone of
therapy in the Intensive Care Unit (ICU), with nearly 50%
of all ICU patients in the US and abroad receiving packed
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red blood cells (pRBCs) during their ICU course [1,2]. At
the same time, a large body of evidence specific to the
acutely ill hospitalized patients indicates that allogeneic
blood is associated with an increased risk of infectious
complications [3-5] and increased hospital length of stay
[6]. Among the critically ill in particular, exposure to
blood has been associated with a substantially increased
risk of nosocomial infection [7-12], multiorgan failure
[13], and death [14].
In addition to infectious complications, there are con-
cerns about transfusion-related immunomodulation and
a shrinking blood supply. Because of these issues, efforts
have focused on ways to minimize an individual's expo-
sure to pRBCs while in the ICU. One such effort was the
TRICC trial [15], which showed that lowering of the trans-
fusion trigger from 10 g/dL (liberal transfusion strategy)
to 7 g/dL (restrictive transfusion strategy) in appropriate
ICU patients results in comparable, and possibly even
somewhat better, outcomes, with a substantial reduction
in blood exposure and utilization. Notably there was a sig-
nificant reduction in certain acute complications in the
restrictive when compared to the liberal transfusion strat-
egy group.
Unfortunately, recent data have indicated that utilization
of the lower trigger is quite variable [1,2,16], particularly
among patients on mechanical ventilation [17]. This indi-
cates that we may be exposing the critically ill patients to
potentially avoidable allogeneic blood, and may in turn
be increasing their risk and overall number of transfusion-
attributable severe acute complications (TSACs). Further-
more, since allogeneic blood carries an economic cost,
there may be an opportunity to improve quality of ICU
care while at the same time saving healthcare dollars via a
restrictive transfusion strategy.
We sought to quantify the potential extent to which reduc-
ing the pre-transfision (pre-TF) hemoglobin (Hb) from
the current practice levels to 7 g/dL, in appropriate
patients, may result in the prevention of transfusion-
attributable severe acute complications (TSACs). We addi-
tionally calculated the potential pRBC units and cost sav-
ings that may be realized with this reduction of overall
utilization of blood. To address these questions, we con-
structed a simulation model based on recently published
studies.
Methods
No human subjects were enrolled in the study, and, thus,
the study was exempt from regulations guiding protection
of human subjects. This is a secondary analysis based on
previously published and peer-reviewed data. All calcula-
tions were performed in Microsoft Excel. Multivariate sim-
ulations and sensitivity analyses were performed using
Crystal Ball® software (Decisioneering, Inc., Denver, CO).
Model overview
We created an analytic model to determine the number of
TSACs avoided annually in the US based on universal
adoption of a restrictive transfusion strategy, defined as a
transfusion trigger of < 7 g/dL [15]. Additionally, we esti-
mated the potential number of units of pRBCs saved and
the direct cost savings that would result from this reduc-
tion in blood utilization. The model was built from the
perspective of a hospital.
Model structure
The model was designed to calculate the net difference in
the frequency of TSACs in the US annually as a function
of the decision to use lower (Hb < 7 g/dL) vs. current (Hb
~8.5 g/dL) transfusion trigger among patients determined
to be at risk for a late transfusion (Figure 1). Late transfu-
sions were defined as those required on and subsequent
to ICU day #3 in the absence of active bleeding. We first
determined the number of complications in a baseline
scenario without the use of lower pre-TF Hb and then sub-
tracted from that the number of complications in a situa-
tion where the trigger of < 7 g/dL was used uniformly. This
equation (and other computations for this analysis) is
illustrated in Table 1.
Model inputs
The number of TSACs annually in the US can be com-
puted based on 1) the estimated US ICU adult population
considered at risk for a late transfusion, 2) the average
Decision tree Figure 1
Decision tree. The square node at the left of the diagram 
represents the decision whether the patient requires a pRBC 
transfusion. The next decision node in the upper tree corre-
sponds to the decision to pursue restrictive vs. usual current 
transfusion strategy. The circular chance nodes represent the 
probability of developing a TSAC with either strategy. The 
rightmost vertical segments are terminal nodes. *ICU, inten-
sive care unit; pRBC, packed red blood cells; TF, transfusion; 
TSAC, transfusion-attributable sever complicationBMC Health Services Research 2007, 7:138 http://www.biomedcentral.com/1472-6963/7/138
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number of pRBCs given to these individuals, and 3) the
risk for a TSAC as a function of the number of pRBC units
transfused. Tables 2, 3, 4 show our estimates for these var-
iables and their sources in the literature. We relied on a
recent epidemiologic survey [18] to approximate the US
ICU population and then assumed 80% of these subjects
were adults [19]. Since the TRICC trial utilized an artifi-
cially high TF trigger of 10 g/dL in the liberal arm, the data
from this arm of the trial could not be used to estimate the
extent of pRBC utilization in the current ICU practice
environment. For this reason, transfusion practice and the
amount of pRBCs given to an average ICU patient in the
absence of a uniform utilization of a restrictive strategy
was abstracted from the placebo arm of a recent rand-
omized trial assessing the impact of recombinant human
erythropoietin (rHuEPO) on transfusion utilization in
critically ill subjects [16]. In this trial there was no uni-
form transfusion protocol, and the mean pre-TF Hb was
8.57 g/dL [16].
To estimate the risk for TSACs we extracted additional
data from the trial by Hebert et al. [15]. In this study sub-
jects were randomized to either a restrictive transfusion
strategy or a liberal approach. We defined as a TSAC all
Table 3: Transfusion-attributable severe acute complications and 
units packed red blood cells/1 transfusion-attributable severe 
acute complications derivation*
Population 
variable
Input Source Output
CV SAC
Liberal 88 (21.0%) Hebert 1999 
[15]
Restrictive 55 (13.2%) Hebert 1999 
[15]
CV TSAC 88-55 Hebert 1999 
[15]
33 (7.8%, 95% 
CI 2.7–12.9%)
ARDS SAC
Liberal 48 (11.4%) Hebert 1999 
[15]
Restrictive 32 (7.7%) Hebert 1999 
[15]
ARDS 
TSAC
48-32 Hebert 1999 
[15]
16 (3.8%, 95% 
CI–0.2–7.8%)
CV+ARDS 
TSAC
33+16 49
Total pRBC 
units TF liberal
5.6 u/pt x 420 
pts TF
Hebert 1999 
[15]
2,352
Total pRBC TF 
restrictive
2.6 u/pt x (418 
x 0.67) pts TF
Hebert 1999 
[15]
728
pRBC units TF 
excess
2,352–728 1,624
pRBC units/1 
TSAC
1,624/49 33
* CV SAC, cardiovascular severe acute complication; CV TSAC, 
cardiovascular transfusion-attributable severe acute complication; 
ARDS SAC, adult respiratory distress syndrome severe acute 
complication; ARDS TSAC, adult respiratory distress syndrome 
transfusion-attributable severe acute complication
Table 1: Analytic framework for the model*
Model variable Input Source/
Calculation
A Total number of ICU admissions 
annually in the US
4.4 mil VERICC [18]
B % Adult ICU admissions 0.8 Groeger 1993 
[19]
C % At risk for a late TF 0.29 Corwin 2002 
[16]
D Mean # units/pt at risk – current 
practice
3.01 Corwin 2002 
[16]
E Mean # units/pt TF – restrictive 
strategy group
2.6 Corwin 2002 
[16]
F Number of patients in restrictive 
group
418 Hebert [15]
G % Patients transfused in restrictive 
group
0.67 Hebert [15]
H Mean # units/pt at risk – restrictive 
practice
1.74 (fxgxe)/f
I Total annual number of units TF – 
current practice
3,073,360 Axbxcxd
j Total annual number of units TF – 
restrictive practice
1,778,234 Axbxcxh
k Total annual number of units TF 
avoided restrictive practice
1,295,126 i-j
l CV+ARDS SACs in liberal group 136 Hebert 1999 
[15]
m CV+ARDS SACs in restrictive 
group
87 Hebert 1999 
[15]
n TSACs 49 l-m
o Total pRBC u TF liberal 2,352 Hebert 1999 
[15]¶
p Total pRBC u TF restrictive 728 Hebert 1999 
[15]¶
q pRBC u TF excess 1,624 o-p
r Units/1 TSAC 33 q/n
s TSACs avoided restrictive practice 39,246 k/r
*ICU, intensive care unit; TF, transfusion; rHuEPO, recombinant 
human erythropoietin; CV, cardiovascular; ARDS, adult respiratory 
distress syndrome; SAC, severe acute complication; TSAC, 
transfusion-attributable severe acute complication; pRBC, packed red 
blood cells; u, unit ¶The total number of units administered was 
calculated by multiplying the mean number of units transfused/patient 
by the number of patients transfused.
Table 2: Annual number of patients at risk for a late transfusion in 
US intensive care units
Population 
variables
Input Source Output
All US ICU 
admissions in 1 
year
4,400,000 VERICC* [18] 4,400,000
% Adults 80% Groeger [19] 3,520,000
% At risk for a 
late TF
29% Corwin [16] 1,020,800
*VERICC, Values, Ethics and Rationing in Critical CareBMC Health Services Research 2007, 7:138 http://www.biomedcentral.com/1472-6963/7/138
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serious cardiovascular complications and cases of ARDS.
We selected these endpoints from that trial as TSAC for
two reasons: 1) they were objectively defined and
recorded and 2) they essentially were shown to occur at
different rates in the liberal and restrictive cohorts. More
specifically, there were 33 fewer cardiovascular complica-
tions and 16 fewer instances of ARDS among those rand-
omized to the restrictive approach (Table 3). We assumed
that any difference in TSACs in the Hebert et al. trial
reflected the results of differential exposure to pRBCs, and
that the relationship between pRBC administration and
TSACs followed a linear dose-response relationship (i.e.,
increasing risks for TSAC increased with greater exposure
to pRBCs [11,12,20]). Dividing the total difference in
TSACs into the calculated aggregate total difference in
units of pRBCs administered between the two arms indi-
cates that for every 33 units of pRBCs avoided, one TSACs
is prevented (Table 3).
To calculate the number of TSACs avoided with the reduc-
tion of the transfusion trigger to 7 g/dL, it was first neces-
sary to assess how many units of pRBCs might potentially
be avoided with the universal use of 7 g/dL as the pre-TF
Hb (Table 4). To evaluate this required two inputs: the
proportion of US adult ICU patients who might be at risk
for late transfusions, and the risk reduction accompanying
change to a restrictive transfusion strategy in the ICU.
Because the literature is vague on the number of patients
remaining in the ICU to constitute the "at risk" group for
late transfusions, we used the percentage of the screened
patients who were deemed eligible for enrollment from
the Corwin[16] study (29%). Next, we utilized the 3.01
units transfused/patient in the placebo group to calculate
the overall blood utilization under current conditions in
the patients at risk. Additionally, based on the experience
of the TRICC investigators [15], we calculated that in the
restrictive group the amount of transfused blood is on
average 1.74 units across all the patients in the group.
Multiplying this by the number of patients at risk yielded
the total blood utilization under the circumstances of uni-
versal adoption of the restrictive transfusion practice. The
difference between blood utilization under current condi-
tions and that under universal use of restrictive practices
was the potential number of pRBC units saved with the
restrictive strategy institution (Table 4). As a final step, to
calculate the potential number of TSACs avoided annually
by using the Hb trigger of 7 g/dL, we simply divided the
calculated number of units per 1 TSAC (n = 33) into the
potential number of units saved with the restrictive strat-
egy (Table 4).
Cost assessment
Calculation of the cost savings associated with the
reduced blood utilization was a simple product of the cur-
rent cost of 1 unit of pRBC and the total number of units
avoided. We determined the costs of a pRBC unit to be
$634 from a report by Cremieux et al. [21] (year 2000 cost
adjusted to 2005 US dollars based on the medical care
services component for the Consumer Price Index).
Monte Carlo simulations and sensitivity analyses
Because of uncertainty surrounding the point estimates
for various model inputs, we conducted several Monte
Carlo simulations and sensitivity analyses to assess the
stability of these observations (Table 5). Monte Carlo sim-
ulation is a technique that allows resampling from the
Table 5: Sensitivity Analyses: Base case and upper and lower 
bound assumptions for the input variables*
Input variable Base case 
assumption
Lower 
bound
Upper 
bound
% Adult ICU patients at 
risk for a late TF
29%a 13%b 50%c
Number of pRBC units/
1 TSAC
33d 19d 552d
Cost per 1u pRBC $634e $250f $800f
*pRBC, packed red blood cells; TF, transfused; TSAC, transfusion-
attributable severe acute complication
aBased on % patients of the total pool screened deemed eligible for 
enrollment into Corwin study16
bBased on % patients of the total pool screened for the TRICC trial 
who gave their consent15
cBased on % patients of the total pool screened for the TRICC trial 
deemed eligible for enrollment15
dBased on 95% CI for the combine CV and ARDS complications from 
Hebert15
eBased on Cremieux21
fBased on anecdotal reports (see text for rationale)
Table 4: Annual packed red blood cell transfusions avoided with 
restrictive transfusion strategy
Population variables Input Source Output
Units pRBC TF/pt placebo 
arm
3.01 Corwin 
2002 
[16]
3.01
Units pRBC TF/pt 
restrictive group
1.74 Hebert 
[15]
1.74
Total units pRBC TF at risk 
ICU patients in 1 year
Current practice 1,020,800 x 3.01 3,073,36
0
Restrictive practice 1,020,800 x 1.74 1,778,23
4
Total units avoided in 1 
year with restrictive 
strategy
3,073,360–
1,778,234
1,295,12
6
pRBC units/1 TSAC 1,624/49 Table 3 33
Total TSACs avoided 1,295,126/33 39,246
PRBC, packed red blood cells; TF, transfusion; pt, patient; TSAC, 
transfusion-attributable severe acute complicationBMC Health Services Research 2007, 7:138 http://www.biomedcentral.com/1472-6963/7/138
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same population while varying several inputs simultane-
ously, thus resulting in random multivariate sampling of
input variables across their corresponding ranges. We var-
ied three inputs across a range of plausible values: the pro-
portion of all adult ICU patients annually at risk for a late
transfusion, the number of pRBCs required to precipitate
one TSAC, and the cost of a unit of pRBC. Each of the out-
comes, total TSACs avoided, total number of pRBCs saved
and the cost savings associated with saving the number of
pRBC units, was tested in 10,000 simulation trials, while
simultaneously and randomly varying the three input val-
ues. Sensitivity analyses were performed to assess which
input variables accounted for the largest amount of varia-
tion in the predicted values of the outcome variables.
For the sensitivity analyses, the lower and upper bounds
for the input variables were derived as follows:
1. The proportion of all adult ICU patients annually at risk
for a late transfusion were obtained from the TRICC trial
(15):
a. Lower bound = percent of the patients of the total pool
screened who gave their consent to participate in the trial
(13%)
b. Upper bound = percent of all patients screened who
were deemed eligible for the study
2. For the number of pRBCs required to precipitate one
TSAC, the upper and lower bounds were obtained using
the 95% confidence interval associated with the reduction
in the risk of these events due to the restrictive transfusion
strategy as compared to the liberal transfusion strategy in
the TRICC trial (15). Specifically, the absolute difference
in TSACs between the liberal and restrictive groups was
adjusted to fall from a lower bound of 3 to an upper
bound of 87. Thus one TSAC is avoided for between 552
units (where the effect of adopting a restrictive strategy
would be the smallest – least effective) to 19 units (where
the effect of adopting a restrictive strategy would be the
greatest – most effective) of pRBCs transfused.
3. Because the cost of a unit of blood varies from region to
region and tends to vary according to the underlying dis-
ease state (21), the upper and lower bounds of cost of a
unit of pRBC were based largely on anecdotal reports of
the cost of blood. To be inclusive, the lower bound used
was $250 and the upper $800.
Results
In our base-case scenario, and based on the inputs and
assumptions described in the Methods section, we esti-
mate that there are 1,020,800 adult subjects in ICUs in the
US annually who may be at risk for a late transfusion
Table 2). Utilizing current transfusion practices, these sub-
jects receive 3,073,360 pRBC units. With the universal
institution of a restrictive practice, the TF burden is
reduced by 42% to 1,778,234 u pRBCs, resulting in a net
savings of 1,295,126 units of pRBCs. Based on our esti-
mated rate of TSACs in this population, this extent of
transfusion avoidance prevents 39,246 additional TSACs
annually, or approximately 1 TSAC per every 26 patients
at risk for a late TF. Total annual blood management costs
under current practice conditions are calculated to be
$1,948,509,929, all due to the costs of pRBCs. With the
restrictive strategy, the estimated cost savings realized
would be $821,109,699 annually.
The base case, lower bound and upper bound values for
the input variables in the simulations are shown in Table
5. After 10,000 trials for each outcome, the median values
(95% confidence intervals) for annualized TSACs
avoided, pRBCs saved and attendant cost savings were
39,246 (2,360 to 43,696), 1,295,126 (753,705 to
2,040,700), and $821,109,699 ($348,827,493 to
$1,310,093,076), respectively. The worst case scenario
was also examined. In the least effective scenario, where
TSACs are infrequent (552 units pRBC/1 TSAC) and the
lowest percentage of patients is at risk for late transfusions
(13%), the number of TSACs avoided would be 1,052
annually. Conversely, in the most effective scenario,
where TSACs are frequent (19 units pRBC/1 TSAC) and
the highest percentage of patients is at risk for late transfu-
sion (50%), there is a potential to avoid 84,137 TSACs.
While it is self-evident that the estimate of the proportion
of ICU patients at risk for late transfusion contributed to
100% of the variability in the estimate of the number of
pRBC units saved, it accounted for 59% of the variability
in the estimated dollars saved, with the uncertainty
around the cost of 1 unit of blood responsible for the
remaining 41% of the variability. As for the variability in
the estimates of the TSACs avoided, the single major con-
tributor to this, with the 90% share, was the uncertainty in
the estimate of the number of pRBC units associated with
1 TSAC; the remaining 10% of this outcome's variability
was due to the uncertainty in the proportion of ICU
patients at risk for a late pRBC transfusion.
Discussion
This model-based simulation quantifies the magnitude to
which the established literature suggests that TSACs are a
significant burden in critically ill patients. Furthermore,
our results indicate that efforts to prevent these TSACs
through transfusion avoidance can enhance outcomes.
Universal adoption of restrictive transfusion strategy rep-
resents one potential tool for transfusion avoidance. Our
model underscores that a restrictive strategy may be a cost-
saving, and thus dominant, option in an anemia manage-BMC Health Services Research 2007, 7:138 http://www.biomedcentral.com/1472-6963/7/138
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ment program, in addition to helping reduce the risk for
the complications following pRBC transfusion.
Prior efforts to explore the relationship between transfu-
sion and its negative sequelae in the ICU have focused on
two areas: nosocomial infection and acute lung injury.
Multiple observational analyses, both retrospective and
prospective, have demonstrated a relationship between
exposure to pRBCs and nosocomial infection. Taylor and
colleagues, for example, in a review of their Project Impact
database demonstrated an independent correlation
between pRBC transfusion and nosocomial infections [8].
Addressing ventilator-associated pneumonia (VAP) spe-
cifically, Shorr et al. demonstrated a link between transfu-
sion and this process [11], while Earley and co-workers
confirmed a connection between transfusion and VAP in
a cohort of trauma patients [20]. Recently Taylor et al. pro-
spectively substantiated the nexus between transfusion
and hospital-acquired infections [22].
Additionally, adverse pulmonary outcomes following
transfusion are now better understood. Transfusion-
related acute lung injury (TRALI) has emerged as a serious
and underappreciated consequence of transfusion.
Although estimated to occur in 1 in 5,000 transfusions,
the incidence is likely higher in critically ill subjects where
the condition may be difficult to distinguish from either
the progression of previously underlying lung injury or
other forms of pulmonary edema. Suggesting the exist-
ence of deleterious pulmonary complications of pRBC
transfusions, Gong et al. reported that transfusion inde-
pendently increased the risk for developing ARDS by 50%
(adjusted odds ratio: 1.52, 95% CI: 1.00–2.31) in ICU
patients with predisposing factors for ARDS [23]. Simi-
larly, Kahn and colleagues in a group of individuals with
subarachnoid hemorrhage noted that pRBC transfusion
independently more than doubled the probability of
ARDS [24]. Most recently another cohort study of nearly
5,000 critically ill patients found an adjusted odds ratio of
2.80 (95% confidence interval 1.90–4.12) of developing
ARDS in association with pRBC transfusions and a dose-
response relationship [25]. Finally, Gajic and coworkers
have demonstrated an 18% absolute reduction in the
development of acute lung injury in association with
instituting a protocol limiting high tidal volume ventila-
tion and inappropriate transfusions [26].
In light of these results, several systematic attempts have
been made to limit the risks related to transfusion. Some
advocate broader use of leukoreduction. Through leuko-
reduction, fewer pro-inflammatory mediators are infused
into the recipient, and in turn, a less intense pro-inflam-
matory response arises. Despite theoretical benefits, it is
unclear if leukoreduction will meaningfully decrease the
rate of TSACs. In a large analysis of the Canadian experi-
ence with leukoreduction, post-transfusion fever was
reduced, but there was no evident impact on nosocomial
infection rates [27]. A recent randomized trial in acute
trauma patients also failed to show any advantages of leu-
koreduction [28].
Recent efforts to limit ICU patients' exposure to allogeneic
blood prompted a number of treatment studies with the
rHuEPO. Thus, a 1999 study by Corwin et al. demon-
strated a nearly 50% reduction in blood utilization, as
well as a trend toward increased transfusion independ-
ence in the rHuEPO group [29]. A large Phase IIB follow-
on trial by the same investigators found a 10% increase in
transfusion avoidance and a 19% decrease in overall
blood utilization [16]. Unfortunately, likely due to sam-
ple size, neither trial demonstrated a reduction in adverse
events that may be attributable to exposure to allogeneic
blood, or a favorable difference in other important out-
comes. A large Phase III study was recently completed and
should shed some light on the outstanding questions of
how rHuEPO may fit into the blood management scheme
in the ICU [30].
Reliance on a restrictive transfusion strategy, on the other
hand, has appeared more successful at altering outcomes.
As noted earlier, Hebert and colleagues showed that lower
levels of hemoglobin are well tolerated in most critically
ill patients, and that in some subjects fewer transfusions
may be associated with improved outcomes [15]. Unfor-
tunately, although some larger institutions appear to have
successfully adopted a restrictive transfusion strategy [31],
it is noteworthy that recent large European and US obser-
vational studies suggest that the transfusion trigger in
most ICUs remains on average at approximately 8.5 g/dL
(1, 2), and is actually even higher in the subgroup of
patients on mechanical ventilation [17].
Why is it important to appreciate the extent of the burden
of TSACs? An outcome has to be measured before it can be
improved. This is most evident with blood stream infec-
tion [12] and ventilator-associated pneumonia
[11,20,32], which have enjoyed improved outcomes
through interventions aimed at their prevention [33,34].
Our study, by estimating their clinical and economic bur-
den, sets the stage for focusing similar efforts to quantify
and prevent some of the avoidable TSACs. An immediate
action that may improve these outcomes is to adhere to
the restrictive transfusion strategy whenever clinically fea-
sible.
Our project's purpose was to determine to what extent
universal adoption of a restrictive transfusion strategy
might enhance efforts at transfusion avoidance and with
what potential direct cost savings to the system. In that
vein, our results show that a restrictive strategy may resultBMC Health Services Research 2007, 7:138 http://www.biomedcentral.com/1472-6963/7/138
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in a substantial benefit to the patient and the system
through avoidance of TSACs. For instance, we calculated
that across-the-board utilization of a restrictive trigger
would result in direct blood cost savings of $821 million
annually. Given that ICU-acquired complications have
substantial humanistic and economic costs [32], this strat-
egy is likely to be even more attractive when one examines
it in the context of ICU outcomes as a whole.
One prior report has attempted to detail the burden of
blood-related complications in the ICU patients [35].
However, their calculations were based on estimates gen-
erated from epidemiologic data dealing with all subjects
transfused, and not only those who are critically ill. As
such, it is not clear that the results from reports dealing
with populations of mixed severity of illness are general-
izable to critically ill subjects. For example, TRALI arising
in an otherwise mildly ill person is likely to have different
consequences than TRALI in an already mechanically ven-
tilated patient. Additionally, Shermock and co-workers
only focused on several well-defined and rare transfusion-
related complications [35]. They addressed viral transmis-
sion, bacterial contamination, and other similar processes
that most clinicians would a priori associate with de min-
imus risk. Although possessing clear diagnostic criteria,
these complications are likely not the major concerns of
the intensivist. Hence, we sought to build and to expand
on their efforts by exploring recently defined complica-
tions of transfusion that have been specifically described
in critically ill patients.
In addition to focusing on outcomes that arise in the ICU,
our analysis has several other strengths. We relied on data
from recent reports describing the results of transfusion in
critically ill patients. Moreover, most of the outcome
inputs used in our model represent results of randomized,
controlled trials [15,16]. Thus differences between those
transfused and not transfused can be assumed to be
directly attributable to added exposure to pRBCs. We also
were conservative in our actual assumptions. Rather than
assuming all subjects in an ICU might be at risk for a late
transfusion, for example, we postulated that about 1/3 of
all subjects might fit into this category. Furthermore, to
formally evaluate the impact of uncertainty surrounding
the point estimates for the model inputs, we conducted
several sensitivity analyses to test the robustness of our
conclusions. Finally, the model's transparency should aid
in its applicability to concrete clinical situations.
Nonetheless, our study has several important limitations.
First, despite our attempt to acknowledge and adjust for
uncertainty, the data from which we draw our model
inputs are limited. Unfortunately there are relatively few
well-done studies exploring transfusion epidemiology,
potential adverse events related to transfusion in the criti-
cally ill, and the significance of adoption of restrictive
transfusion strategy in the ICU in the real world. Studies
quantifying the actual cost of blood in the ICU setting are
scarce as well. For this reason our final sensitivity esti-
mates are relatively broad and imply intrinsic sensitivity
to the accuracy of the input variables' values. That is, the
most significant influence on the number of TSACs
avoided in the least effective scenario is the assumption
that it takes 552 units to precipitate 1 TSAC. While this
number is based on the 95% confidence intervals
reported by Hebert [15], it needs to be viewed in the con-
text of observational studies that suggest a much greater
incremental risk associated with exposure to each unit of
pRBCs [8,11,12]. Second, we assumed that the incidence
of our primary outcomes of interest, cardiovascular com-
plications and ARDS/ALI, follows a linear dose-response
relationship with pRBC exposure. Although some obser-
vational studies suggest this to be the case [11,12,22], to
the best of our knowledge, no well-designed prospective
study has been carried out to confirm this. In reality, both
of these adverse outcomes might not be linearly related to
pRBC transfusion amounts, but could alternatively follow
a threshold effect. Third we did not add the economic or
clinical cost of an actual TSAC into our model due to the
paucity of such data in peer-reviewed literature. Fourth,
the data on liberal transfusion-associated complications
are derived from a single trial [15]. This may be problem-
atic in several ways: 1). Risk estimates from a trial may not
reflect accurately the risks in real practice, and 2). Given a
vast list of exclusion criteria and treating physician's dis-
cretion with respect to the decision to enroll patients, the
results may not be generalizable to all ICU patients. Since
a similar study is not likely to be replicated in subpopula-
tions of patients of interest, we have attempted to over-
come these short-comings by performing sensitivity
analyses utilizing fairly conservative risk estimates and
thus biasing the model against restrictive strategy. How-
ever, the possibility remains that by applying the strategy
across the board, our model may thus overestimate the
true effect that the institution of a sensible restrictive prac-
tice appropriate to a multitude of clinical situations would
have. Finally, the sources for some of the critical inputs
were derived from two different trials with potentially dif-
ferent populations. To assess this, we examined the poten-
tial differences between the restrictive strategy group in
the TRICC trial and the placebo arm in the Corwin study
(Table 6) [15,16]. Although the placebo group in the Cor-
win trial (n = 652) was slightly larger than the restrictive
arm in the TRICC study (n = 418), they were similar in
their mean age, gender distribution and APACHE II
scores. As for primary diagnoses, there was an imbalance
between the groups in the proportion of patients with
trauma, 20% vs. 48.5%, and cardiovascular disease, 18%
vs. 5.4%, in TRICC and Corwin, respectively. While a def-
icit of cardiovascular diagnoses may have biased the Cor-BMC Health Services Research 2007, 7:138 http://www.biomedcentral.com/1472-6963/7/138
Page 8 of 9
(page number not for citation purposes)
win placebo arm in the direction of a restrictive strategy,
the excess of trauma patients would operate in the oppo-
site direction, potentially biasing against a restrictive strat-
egy. However, these limitation notwithstanding, to the
best of our knowledge, ours is the first study to estimate
the plausible range of avoidable costs and complications
is restrictive transfusion strategy were to be adopted more
uniformly in the ICUs across the US.
Conclusion
Our model estimates that universal adoption of a restric-
tive transfusion strategy could result in avoidance of
nearly 40,000 transfusion-attributable severe acute com-
plications annually among the critically ill in the US. This
in turn could result in the savings of nearly $1 billion in
costs associated with blood alone to the healthcare sys-
tem. Furthermore, these findings remain robust across a
range of sensitivity analyses. Efforts should be undertaken
to support more ubiquitous adoption of a clinically
appropriate restrictive transfusion strategy in the ICU.
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